Harry P. Erba, MD; Jorge E. Cortes, MD; and Michael Mauro, MD, reflect on the value of having 4 BCR-ABL tyrosine kinase inhibitors as frontline therapy options for patients with chronic myeloid leukemia and discuss how to stratify patients for treatment.